Current and Recent Projects
The Forum HIV Cure Research Project will convene a series of meetings to address the clinical trial and regulatory issues surrounding HIV cure research. Focusing on the ethical, regulatory and clinical factors of HIV cure research, the project will utilize the traditional Forum approach of engaging key stakeholders, including those from the FDA, NIH, academia, advocates, and industry.
The HCV Drug Development Advisory Group (DrAG) is a unique forum that brings together representatives from the U.S. and European regulatory agencies, academia, patient advocates and the pharmaceutical industry to build consensus around drug development-related issues. This Q&A video series features the reflections of several DrAG members on the impact the group has had on HCV drug development.
With a number of first-line regimen drug patents expiring in the next few years, the availability of generic antiretrovirals (ARVs) will be an unprecedented occurrence in the history of the treatment of HIV infection. Recent studies have demonstrated that a 3-pill, generic-based regimen (two generics, one branded) has the potential for significant price reductions. However, patients and providers have expressed concerns about potential consequences including: 1) increased pill burden, 2) decreased treatment adherence, and 3) the quality of generic drugs.